Cost effectiveness analysis of HMG-COA reductase inhibitors in a medicaid population

被引：0
|
作者：
MacLean, EA [1 ]
Moffitt, CM [1 ]
机构：
[1] Pfizer Inc, Wakefield, RI USA
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)64149-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：319 / 320
页数：2
相关论文
共 50 条
  • [1] Are HMG-CoA reductase inhibitors cost effective?
    Drugs & Therapy Perspectives, 1997, 9 (9) : 14 - 16
  • [2] Critical evaluation of a cost-effectiveness analysis of four HMG-CoA reductase inhibitors
    Cox, ER
    Griffis, DL
    FORMULARY, 1999, 34 (12) : 1041 - +
  • [3] HMG-COA REDUCTASE INHIBITORS
    ENDO, A
    ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, 1985, 183 : 295 - 310
  • [4] HMG-COA REDUCTASE INHIBITORS
    ENDO, A
    HASUMI, K
    NATURAL PRODUCT REPORTS, 1993, 10 (06) : 541 - 550
  • [5] HMG-COA REDUCTASE INHIBITORS
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 1988, 40 (06): : 477 - 477
  • [6] HMG-CoA reductase inhibitors
    Illingworth, DR
    Tobert, JA
    ADVANCES IN PROTEIN CHEMISTRY, VOL 56: DRUG DISCOVERY AND DESIGN, 2001, 56 : 77 - 114
  • [7] HMG-COA REDUCTASE INHIBITORS
    GRUNDY, SM
    JOURNAL OF INTERNAL MEDICINE, 1990, 228 (03) : 201 - 205
  • [8] HMG-CoA reductase inhibitors
    不详
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1996, 6 (01) : 77 - 78
  • [9] Various HMG-CoA reductase inhibitors
    Thiery, J
    Seidel, D
    INTERNIST, 1999, 40 (01): : 113 - 114
  • [10] HMG-CoA reductase inhibitors and the kidney
    Vito M. Campese
    Bassel Hadaya
    Josephine Chiu
    Current Hypertension Reports, 2005, 7 : 337 - 342
12345